ORS Price

Overview

Welcome to Dwaey, specifically on ORS page.
This medicine contains an important and useful components, as it consists of
ORS - Dextrose (anhydrous), Potassium chloride, Sodium chloride, Trisodium citrate dihydrateis available in the market in concentration

Name

Raloxifene Hydrochloride

Precaution

Before initiating **Raloxifene Hydrochloride** therapy, it is crucial to consult a healthcare provider to determine if the drug is appropriate for the individual’s specific condition. Some key precautions include: - **Venous Thromboembolism (VTE)**: Raloxifene can increase the risk of **deep vein thrombosis (DVT)**, **pulmonary embolism (PE)**, and other thromboembolic events, particularly in patients with a history of **blood clots** or those who are **immobilized**. It should be used with caution in such individuals. - **Pregnancy and Breastfeeding**: Raloxifene is contraindicated in **pregnancy** and should not be used during **breastfeeding** as it can harm the fetus and may be excreted in breast milk. - **Stroke Risk**: Patients with a history of **stroke** or those at increased risk for stroke should be monitored closely when using raloxifene due to potential cardiovascular side effects. - **Liver Disease**: Raloxifene should be used cautiously in patients with **liver dysfunction** or **hepatic impairment**. Regular liver function tests are recommended during treatment. - **Bone Fractures**: Though raloxifene helps to prevent bone loss, it should be used carefully in individuals who are at high risk for **bone fractures**, and additional treatments for bone health may be considered.

Indication

**Raloxifene Hydrochloride** is primarily indicated for the treatment and prevention of conditions related to **osteoporosis** and **estrogen-related diseases**: - **Osteoporosis**: Raloxifene is used in postmenopausal women to prevent and treat **osteoporosis**, a condition where bones become weak and brittle, increasing the risk of fractures. - **Breast Cancer Prevention**: Raloxifene is approved for reducing the risk of **invasive breast cancer** in postmenopausal women who have **osteoporosis** or are at high risk for breast cancer. - **Postmenopausal Osteopenia**: Raloxifene is used to prevent bone loss in women who do not yet have osteoporosis but are at risk for the condition due to estrogen deficiency. - **Cardiovascular Protection**: Though not primarily used for this purpose, raloxifene has been shown to have potential **cardioprotective effects** in postmenopausal women by improving **lipid profiles** (lowering **LDL cholesterol** and increasing **HDL cholesterol**).

Contra indication

Raloxifene should not be used in certain conditions due to potential health risks: - **Pregnancy**: Raloxifene is contraindicated during **pregnancy** due to its potential harm to the fetus. - **Lactation**: The drug should not be used during **breastfeeding** as it may be excreted in breast milk and could affect the infant. - **History of Venous Thromboembolism**: Raloxifene is contraindicated in patients with a history of **DVT**, **pulmonary embolism**, or other thromboembolic disorders. - **Active Liver Disease**: Patients with **severe hepatic impairment** or **active liver disease** should avoid using raloxifene. - **Known Hypersensitivity**: Individuals who have shown an allergic reaction to **raloxifene** or any of its components should not take the medication.

Side Effect

While **Raloxifene** is generally well-tolerated, it can cause both **common and serious side effects**: **Common Side Effects**: - **Hot Flashes**: A common side effect, especially in postmenopausal women, is the occurrence of **hot flashes** or a sensation of warmth, often accompanied by sweating. - **Leg Cramps**: Some patients may experience **leg cramps**, particularly at night. - **Joint Pain**: Mild **joint pain** or **musculoskeletal pain** has been reported in some users. - **Sweating**: Increased sweating may also occur in some patients. **Serious Side Effects**: - **Venous Thromboembolism (VTE)**: The most serious side effect is an increased risk of **deep vein thrombosis (DVT)**, **pulmonary embolism (PE)**, and other blood clots, particularly in women who are immobilized or have a history of clotting disorders. - **Stroke**: Raloxifene may increase the risk of **stroke** in certain populations, particularly those with existing cardiovascular risk factors. - **Liver Dysfunction**: Although rare, raloxifene can cause **elevated liver enzymes**, which may indicate **liver damage**. Symptoms like **yellowing of the skin or eyes** should be reported immediately. - **Pregnancy-related Risks**: Raloxifene is contraindicated during pregnancy, and its use may cause **harmful effects on the fetus** if taken during this time.

Pregnancy Category ID

5

Mode of Action

Raloxifene is a **selective estrogen receptor modulator (SERM)** that has estrogen-like effects on some tissues and anti-estrogen effects on others: - **Bone**: Raloxifene acts as an **estrogen agonist** in bone tissue, promoting **bone density** and reducing **bone resorption** (breakdown of bone tissue). This helps prevent bone loss in postmenopausal women and reduces the risk of fractures. - **Breast and Uterus**: In the **breast** and **uterine tissues**, raloxifene acts as an **estrogen antagonist**, blocking estrogen's effects and thereby reducing the risk of **estrogen-driven breast cancer**. - **Liver and Lipid Profile**: Raloxifene also helps to improve the **lipid profile** by reducing **LDL cholesterol** (bad cholesterol) and increasing **HDL cholesterol** (good cholesterol), providing **cardiovascular protection**. Raloxifene mimics some of the benefits of estrogen, particularly on bone health, without stimulating the uterus or breast tissue, making it beneficial for preventing osteoporosis and breast cancer in postmenopausal women.

Interaction

Several drugs and substances may interact with **Raloxifene Hydrochloride**, which can affect its effectiveness or safety: - **Bile Acid Sequestrants**: **Bile acid sequestrants** (such as **cholestyramine**) can reduce the absorption of raloxifene. It is advised to take raloxifene at least **1 hour before or 4-6 hours after** taking these medications. - **Estrogen**: Concomitant use of raloxifene with **estrogen** products (such as hormone replacement therapy) may increase the risk of **thromboembolic events**. Estrogen therapy should generally be avoided during raloxifene treatment. - **Warfarin**: The **blood-thinning** effects of **warfarin** may be affected by raloxifene, so careful monitoring of **INR (international normalized ratio)** is necessary. - **Other Medications Affecting Clotting**: Medications that influence clotting, such as **aspirin** or **nonsteroidal anti-inflammatory drugs (NSAIDs)**, may increase the risk of **bleeding** when taken with raloxifene. Patients should be closely monitored. - **Corticosteroids**: Long-term use of **corticosteroids** can increase the risk of **bone loss** and may reduce the efficacy of raloxifene.

Pregnancy Category Note

Information not available

Adult Dose

The typical **adult dose** of **Raloxifene Hydrochloride** is: - For the treatment and prevention of **osteoporosis**, the recommended dose is **60 mg** once daily, taken with or without food. - For **breast cancer prevention**, the dose is also **60 mg** once daily. The dose should be taken at the same time each day to help remember and maintain a consistent routine. **Raloxifene** should be used long-term for maximum benefit in preventing bone loss and reducing the risk of fractures.

Child Dose

Raloxifene is **not recommended for use in children**, as there is limited data on its safety and effectiveness in pediatric populations. It is specifically approved for **postmenopausal women** and should be avoided in individuals under the age of 18. As with any medication, it is essential for patients to consult their healthcare provider prior to starting **Raloxifene Hydrochloride** to ensure it is safe based on their individual health status and medical history.

Renal Dose

No dosage adjustments are typically necessary for patients with **mild to moderate renal impairment**. However, **caution** is advised for patients with **severe renal impairment**, and close monitoring may be required to ensure safety. If you have any kidney-related issues, it is critical to consult with a healthcare provider before starting or adjusting the dose.

Administration

Information not available